All In Biotech

Drug Trial Radar · NCT05687890

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

255

Actual

Start

May 23, 2023

Primary completion

Nov 30, 2024

Study completion Apr 2025

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.

Conditions

  • Diabetic Kidney Disease
  • IgA Nephropathy

Interventions

  • Placebo of SC0062Drug

    Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

  • SC0062 low doseDrug

    Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

  • SC0062 medium doseDrug

    Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

  • SC0062 high doseDrug

    Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in urine albumin creatinine ratio (UACR)Time frame: Week 12
  2. Changes in urine protein creatinine ratio (UPCR)Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 79 Qingchun Rd.,Shangcheng District

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.